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Abstract
Background: Targeted inhibition of protein kinases is now acknowledged as an effective approach for
cancer therapy. However, targeted therapies probably have limited success because cancer cells have
alternate pathways for survival and proliferation thereby avoiding inhibition. We tested the hypothesis that
combination of targeted agents would be more effective than single agents in arresting melanoma cell
proliferation.
Methods: We evaluated whether BAY43-9006, an inhibitor of the B-Raf kinase, and rapamycin, an
inhibitor of the mTOR kinase, would inhibit serum-stimulated proliferation of human melanoma cell lines,
either alone or in combination. Proliferation was measured by quantitating melanoma cell numbers with a
luciferase for ATP. Phosphorylation of proteins downstream of targeted kinase(s) was assayed by
immunoblots. Statistical significance was determined with the Student-T test. Isobologram analysis was
performed to distinguish additive versus synergistic effects of combinations of drugs.
Results: Serum-stimulated proliferation of multiple human melanoma cell lines was inhibited by BAY43-
9006 and by rapamycin. Melanoma cells containing the B-Raf mutation V599E were more sensitive than
cells with wild-type B-raf to 10 nM doses of both BAY43-9006 and rapamycin. Regardless of B-Raf
mutational status, the combination of low dose rapamycin and BAY43-9006 synergistically inhibited
melanoma cell proliferation. As expected, rapamycin inhibited the phosphorylation of mTOR substrates,
p70S6K and 4EBP1, and BAY43-9006 inhibited phosphorylation of ERK, which is dependent on B-Raf
activity. We also observed unexpected rapamycin inhibition of the phosphorylation of ERK, as well as
BAY43-9006 inhibition of the phosphorylation of mTOR substrates, p70S6K and 4EBP1.
Conclusion: There was synergistic inhibition of melanoma cell proliferation by the combination of
rapamycin and BAY 43-9006, and unexpected inhibition of two signaling pathways by agents thought to
target only one of those pathways. These results indicate that combinations of inhibitors of mTOR and of
the B-raf signaling pathways may be more effective as a treatment for melanoma than use of either agent
alone.
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Background
In human cancers, mutant oncogenes are frequently asso-
ciated with disease progression [1]. Thus, there is a need
for development of effective therapies that can slow pro-
gression of solid tumors by blocking the action of those
oncogenes. Cancer therapy has undergone a paradigm
shift based on the therapeutic effectiveness of imatinib
mesylate (Gleevec). This drug was designed as a specific
inhibitor of the BCR-ABL oncogene protein tyrosine
kinase, known to be responsible for chronic myeloid
leukemia (CML) cells [2]. The therapeutic effectiveness of
Gleevec and relative absence of detrimental side-effects
has made it a model for the development of an array of
new therapeutic agents targeted to inhibit signal transduc-
tion enzymes, especially protein kinases.
The recent discovery that 60–70% of human melanomas
have activating mutations in B-Raf (with 80% of these
mutations caused by a single substitution V599E) make
this protein kinase an especially promising target for inhi-
bition [3,4]. Indeed, lead compounds have been pro-
duced and tested, and currently are working their way
through clinical trials. One example is BAY43-9006 (aka:
sorafenib,  N-(3-trifluoromethyl-4-chlorophenyl)-N'-(4-
(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea), an
investigational compound, currently in phase II and III
clinical trials, designed to inhibit both B-Raf and C-Raf
kinases [5,6]. B-Raf is a component of a cell signaling
pathway which includes the upstream activator of Raf,
called Ras, and the direct substrate of Raf, called MEK1/2
and the MEK substrate ERK1/2 [7]. B-Raf phosphorylates
MEK1 and MEK2 on Ser217 and Ser221, which activates
it to dual phosphorylate ERKs, at Thr202/Tyr204 for
human ERK1 and Thr185/Tyr187 for human ERK2 [8,9].
Mutations in RAF which cause constitutive activation of
Raf kinase are thought to promote events leading to car-
cinogenesis. Pre-clinical and early phase I studies have
suggested that BAY 43-9006 may be of therapeutic value
not only in human tumors containing ras gene mutations,
but also in tumors over-expressing growth factor receptors
that activate the Ras/ERK pathway [10]. However, these
studies have not addressed the effects of BAY 43-9006 in
combination with any other kinase inhibitors.
Another molecular pathway commonly mutated (30–
60%) in melanomas involves loss of the PTEN tumor sup-
pressor gene, which can lead to constitutive activation of
the mTOR kinase signaling pathway [11-13]. Inhibition of
mTOR kinase is feasible with the macrolide natural prod-
uct rapamycin (aka: sirolimus, RAPA, Rapamune, AY-
22989, and NSC-226080). Rapamycin is an FDA-
approved agent used as immunosuppressive therapy post
organ transplant [14,15]. More recent clinical application
of rapamycin has been with coated stents to suppress the
neo-intima formation during restenosis in response to
balloon angioplasty [16]. The action of rapamycin is
understood to involve binding to the receptor protein
FKBP12; this drug-protein complex binds to the mTOR
protein kinase and interferes with phosphorylation of two
well-recognized downstream targets, p70S6K (p70 ribos-
omal S6 kinase) and 4EBP1 (aka: 4E binding protein 1,
eukaryotic translation initiation factor 4E binding pro-
tein, and PHAS-1) [17]. An appreciation of the potent
inhibition of cell growth and protein synthesis, as well as
cell cycle arrest, imposed by rapamycin led to testing of its
derivatives, in particular CCI-779, as cytostatic agents,
especially for various cancers refractory to other forms of
cancer chemotherapy [18-20]. Pharmacokinetic analysis
revealed that CCI-779 was progressively converted into
rapamycin, its main metabolite, beginning as early as 15
minutes after infusion of the drug [20], therefore, we used
rapamycin in our studies.
Our interest is in combining targeted agents for these
pathways in an effort to determine if such treatments will
be effective in the treatment of melanoma. We hypothe-
sized that the combination of multiple targeted therapeu-
tic agents would result in enhanced inhibition of
melanoma cell proliferation compared to either drug
alone, because of synergy between effects on two path-
ways. Here we show that serum-stimulated melanoma cell
proliferation is inhibited by either rapamycin or BAY43-
9006, with B-Raf V599E mutants showing an increased
sensitivity to each drug at 10 nM compared to melanoma
cells with wild-type B-Raf. Each of these drugs inhibited
the serum-stimulated phosphorylation of known Raf and
mTOR substrates. What was unexpected was that each of
the drugs inhibited phosphorylation in both the Raf and
mTOR pathways, suggesting there was interdependence or
cross-talk between these pathways in melanoma cells. Fur-
thermore, the combination of rapamycin with BAY43-
9006 was synergistic compared to either drug alone at
inhibiting proliferation of wild-type B-Raf and V599E
mutant B-Raf melanoma cell lines.
Methods
Cell Culture
Melanoma cell lines used in this study were derived from
tumors from patients at the University of Virginia
(VMM5A, VMM18, and VMM39), as described previously
[21,22]. All of the cell lines were cultured in RPMI 1640
medium supplemented with 5% fetal bovine serum, 2
mM L-glutamine, penicillin (100 units/ml), and strepto-
mycin (100 µg/ml) at 37°C in 5% CO2, unless otherwise
indicated. As a control, cells were incubated in Dulbecco's
Phosphate buffered saline (PBS). VMM39 is a representa-
tive cell line from human melanomas known to contain a
wild-type B-Raf gene and VMM18 and VMM5A both con-
tain the V599E B-Raf activating mutation [23]. Other
human melanoma cell lines listed in Table 1 includeJournal of Translational Medicine 2005, 3:39 http://www.translational-medicine.com/content/3/1/39
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VMM12, a malignant melanoma cell line derived from
tumors from a patient at the University of Virginia which
is known to contain the V599E B-Raf activating mutation
[23]. DM122 is a melanoma cell line derived from tumors
from a patient at Duke University, and is known to con-
tain a wild-type B-Raf gene (data not shown). DM6 and
DM331 are melanoma cell lines derived from tumors
obtained from patients at Duke University, however, their
B-Raf status remains to be determined.
Reagents and Inhibitors
The MEK1/2 inhibitor U0126 (Catalog # 662005) and
BAY43-9006 (Catalog # 553011) were purchased from
Calbiochem, and stock solutions were made in DMSO.
Rapamycin (R-5000) was purchased from LC Laboratories
and a stock solution was made in DMSO.
Cell Proliferation Assays
Melanoma cells (25,000 cells per well) were plated in 96-
well plates in RPMI plus either 5% FBS or 0.5% FBS, and
cell numbers were assayed at time 0 and after 4, 8, 16, 24,
48, and 72 hours using Cell Titer 96 Aqueous (Promega
Catalog# G3580; Madison, WI), according to the instruc-
tions provided by the manufacturer. Serum-dependent
rates of growth were calculated using the slope of the lines
from the growth curves, as shown in Figure 1A for
VMM18. For experiments to examine the effects of the sig-
nal transduction inhibitors on serum-dependent
melanoma cell proliferation, melanoma cells (1,000 cells
per well) were plated in triplicate in a 96-well plates with
5% fetal bovine serum and allowed to adhere overnight.
After 12–16 h, the cells were washed and treated with
inhibitors as indicated for one hour. Cells were then
washed and grown in RPMI medium with 5% FBS for 48
hours. Cell numbers were assayed with Cell Titer-Glo
(Promega Catalog # G7571) according to the instructions
provided by the manufacturer. The triplicate values were
all within 5% and the mean values were calculated and
plotted with error bars representing the standard devia-
tion of triplicate samples from 3 independent experi-
ments.
Western Blot Analysis
For analysis of proteins in Figure 1B and 1C, VMM5A,
VMM18, and VMM39 melanoma cells were plated in Petri
dishes and incubated for 24 hours in either RPMI medium
plus 5% FBS or 0.5% FBS. After 24 hours, the cells were
harvested and lysed as described for analysis of proteins in
Figures 4 and 5. For analysis of the proteins in Figures 4
and 5, VMM18 melanoma cells were plated in petri
dishes, treated with drugs or not for one hour, washed,
and incubated overnight in RPMI medium plus 5% FBS.
The next day, cells were rinsed with room temperature
PBS, frozen by placing the dish on a mixture of acetone
and dry ice. Cells were lysed in one ml of ice-cold 5%
trichloroacetic acid for 10 minutes, scraped from the dish
using a Costar cell lifter and the slurry was transferred to a
1.5-ml microcentrifuge tube and centrifuged for 10 min-
utes at 10,000 × g. The supernatant was discarded, and the
pellet was washed twice with cold acetone to extract away
the trichloroacetic acid and the proteins resuspended in
resolubilization buffer (20 mM Tris, 23 mM glycine, 1
mM EDTA, and 10 mM β-glycerophosphate). Protein
yields were determined by BCA analysis. Proteins were
resuspended in SDS-containing sample buffer, heated for
10 min at 100°C, and 10 ng/lane was resolved by SDS-
PAGE and transferred to Immobilon-P (Millipore). Mem-
branes were blocked in 1% BSA in 50 mM Tris-Cl (pH
7.5), 0.9% NaCl, 0.05% Tween 20, and 0.01% antifoam
A. Membranes were probed with antibodies listed below.
Proteins were detected with Pierce SuperSignal West Pico
Chemiluminescent substrate (#34080) as recommended
by the manufacturer and used to expose to Kodak BioMax
film. Films exposed within the linear response range were
scanned and used for densitometry analysis by Image
Quant 5.2.
Antibodies
Anti-p70S6 Kinase, clone SB20 Antibody (Catalog # 05-
781, used at 1:8000) was purchased from Upstate. 4E-BP1
Antibody (Catalog #9452, used at 1:500) was purchased
from Cell Signaling. GAPDH Antibody (Catalog #
MAB374, used at 1:500) was purchased from Chemicon
International. Anti-phospho MAP Kinase (ERK1/2), clone
12D4 antibody (Catalog # 05-481, used at 1:500) was
purchased from Upstate. Anti-MAP Kinase 2/ERK2 anti-
body (Catalog #06-333, used at 1:500) was also pur-
chased from Upstate. Phospho-MEK1/2 (Ser217/221)
Antibody (Catalog#2354S, used at 1:1000) was purchased
from Cell Signaling. Anti-Mouse IgG, peroxidase-linked
species-specific whole antibody from sheep, secondary
antibody (Catalog #NA931, used at 1:5000) was pur-
chased from Amersham Biosciences. Anti-rabbit IgG, per-
oxidase-linked species-specific whole secondary antibody
Table 1: Melanoma cell proliferation is stimulated by serum.
Cell Line
VMM18 2.0
DM6 2.3
VMM39 2.1
VMM5A 2.0
VMM12 2.4
DM331 1.7
DM122 2.0
FoldIncrease
5.0%
0.5%





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A, Growth curves of VMM18 melanoma cells in 5% and 0.5% serum-containing media Figure 1
A, Growth curves of VMM18 melanoma cells in 5% and 0.5% serum-containing media. VMM18 melanoma cells were cultured in 
media containing either 5% or 0.5% serum and were assayed in triplicate at times 0, 4, 8, 16, 24, 48, and 72 hours using Cell 
Titer 96 Aqueous (Promega; Madison, WI) according to the directions supplied by the manufacturer. The absorbance at 490 nm 
(OD 490) measures the quantity of formazan product from the MTS-based assay and is directly proportional to the number of 
live cells present. The R2 values for the linear regression lines determined using Microsoft Excel are listed above each line. The 
solid dark line with the squares represents the data collected from VMM18 melanoma cells grown in media with 5% serum. The 
thin line with the circles represents the data from VMM18 melanoma cells grown in media containing 0.5% serum. B, Western 
blot analysis of 4EBP1 from melanoma cell lines grown in 5.0% FBS and 0.5% FBS. Phosphorylation of 4EBP1 was assayed by its 
reduced migration in SDS-PAGE and the proteins were detected by immunoblotting. VMM5A, VMM18, and VMM39 cells were 
grown in media as indicated. C, Western blot analysis of ERK from melanoma cell lines grown in 5.0% FBS and 0.5% FBS. The 
dual phosphorylation of ERK was analyzed by phosophosite-specific immunoblotting in VMM5A, VMM18, and VMM39 
melanoma cells cultured as described (upper panel). The total amount of ERK protein was determined by immunoblotting with 
a separate antibody (lower panel). The relative phosphorylation of ERK was quantitated by densitometry analysis using Image 
Quant 5.2 software and the values are given below the top panel.
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from donkey (Catalog # NA934, used at 1:5000) was also
purchased from Amersham Biosciences.
Isobologram Analysis
To assess whether a combination dose of rapamycin and
BAY43-9006 is synergistic or simply additive, a focused
isobologram method was used as described previously
[24]. An IC70 was selected, and these doses of each drug
alone were plotted as the ordinate and abscissa in a Carte-
sian log-log plot. The straight line connecting these IC70
values is the locus of points (dose pairs) that produce a
simply additive combination. In an isobologram, the
IC70 dose pairs for two drugs together which fall on the
line indicate an additive effect. Points above this line indi-
cate antagonism, and points below the line indicate syn-
ergism.
Human Subjects
All of the research involving human subjects was
approved by the University of Virginia's IRB (Human
Investigation Committee) in accordance with assurances
filed with and approved by the Department of Health and
Human Services. Informed consent was obtained from all
of the study participants.
Results
Proliferation of melanoma cells expressing wild-type and 
V599E mutant B-Raf
We examined the serum-dependent proliferation of vari-
ous human melanoma cell lines. Figure 1 A is a growth
curve for the VMM18 cell line, which is representative of
the growth curves generated for each of the cell lines from
a collection of human melanomas (Table 1). Cell prolifer-
ation was determined by the number of cells at 0, 4, 8, 16,
24, 48, and 72 hours, quantitated using the Cell Titer 96
Aqueous (Promega Corporation, Madison, WI) assay
which measures reduction of MTS (a novel tetrazolium
compound). These human melanoma cell lines prolifer-
ated even in limiting serum (0.5%). However, all showed
higher rates of proliferation ~ 2-fold in the presence of 5%
serum.
We could detect activation of the mTOR and ERK signal-
ing pathways in proliferating melanoma cells. Shown in
Figure 1 B is a Western blot detecting the phosphorylation
of the mTOR substrate, 4EBP1, from 3 different
melanoma cell lines grown in the presence of either 5% or
0.5% serum. The phosphorylation of 4EBP1 has previ-
ously been demonstrated to retard migration in SDS-
PAGE [25], seen as the upper band in the doublet in the
even numbered lanes (Figure 1B). Shown in Figure 1 C is
a Western blot detecting both the dual phosphorylated
(activated) form of ERK, as well as total ERK protein in
three different melanoma cell lines grown in 5% or 0.5%
serum. The quantitation of the relative phosphorylation
of ERK relative to total ERK is shown between the blots,
demonstrating about a two-fold increase in phosphoryla-
tion. The phosphorylation of ERK paralleled the relative
increase in proliferation for each of these cell lines.
BAY43-9006 and rapamycin inhibit proliferation of 
melanoma cells
We examined the serum-dependent proliferation of mul-
tiple human melanoma cell lines and the effects of inhibi-
tion of B-Raf by BAY43-9006 and of mTOR by rapamycin.
Melanoma cell lines were tested for proliferation after
treatment with a single dose of BAY43-9006 or rapamycin
using Cell Titer-Glo (Promega Corporation, Madison,
WI), a luminescence-based ATP cell viability assay. Cells
were exposed to different doses of either drug for one
hour. Then, the media was changed and the cells were cul-
tured for two days in the presence of serum. We found that
micromolar concentrations were cytotoxic, because cell
numbers decreased after two days, whereas nanomolar
concentrations were growth inhibitory. Melanoma cells
showed dose-dependent inhibition with 0.01 nM to 100
nM of BAY43-9006 (Figure 2A), or rapamycin (Figure 2B).
Proliferation of the cells was inhibited in either 5% or
0.5% serum.
Among the melanoma cell lines, there was a significant
difference in the amount of inhibition at 10 nM BAY43-
9006 or rapamycin. We observed that melanoma cell lines
that contain the V599E mutation in B-Raf (VMM5A and
VMM18) were more sensitive to BAY43-9006 and to
rapamycin, compared to cell lines with wild-type B-Raf
(VMM39). This difference in growth inhibition was
observed in two additional cell lines, one wild-type
(DM122) and one V599E (VMM12). Therefore, nanomo-
lar concentrations of either BAY43-9006 or rapamycin
inhibit the proliferation of melanoma cells, whether or
not they have mutated B-Raf.
Combining Rapamycin with BAY43-9006 synergistically 
inhibits serum-dependent proliferation of melanoma cells
Melanoma cell proliferation was inhibited by either
BAY43-9006 or rapamycin over the 0.01 – 100 nM con-
centration range. A combination of the two drugs was
markedly more effective than either drug alone at inhibit-
ing serum-stimulated melanoma cell proliferation. For
example, 0.01 nM of each drug together was more effec-
tive at inhibiting melanoma cell proliferation than 1 nM
of either drug alone. To assess synergism versus additivity
quantitatively, we used a focused isobologram method
(Figure 3). Treatment of three melanoma cell lines
(VMM39, VMM5A, and VMM18) with rapamycin alone
induced a 70% growth inhibition (IC70) from approxi-
mately 10 nM (VMM39) to 2 nM (VMM5A and VMM18).
These were plotted on the ordinate. The IC70 concentra-
tion for BAY43-9006 alone was in the range of approxi-Journal of Translational Medicine 2005, 3:39 http://www.translational-medicine.com/content/3/1/39
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mately 5 to 10 nM, in different cell lines, and these were
plotted on the abscissa. Compared to the single agents,
the IC70 for the dose pairs (rapamycin and BAY43-9006
together) falls below the line, for each of these melanoma
cell lines, indicating that the combination is synergistic
(Figure 3). Furthermore, VMM18, which contains the
V599E substitution, was more sensitive to the combina-
tion treatment than melanoma cell lines with wild-type B-
Raf, consistent with the enhanced sensitivity at the 10 nM
dose of each agent (Figure 2 above). However, all
melanoma cell lines tested displayed synergistic inhibi-
tion of proliferation, indicating that these drugs were
more effective in combination than alone.
Rapamycin and BAY43-9006 inhibit phosphorylation of 
proteins in the mTOR signaling pathway in melanoma cells
Melanoma cells were treated with rapamycin and BAY 43-
9006, either singly or in combination, for one hour, and
protein phosphorylation was examined by Western blot
analysis 24 hours later. Rapamycin is an inhibitor of
mTOR kinase and reduces phosphorylation of its sub-
strates, p70S6K and 4EBP1 [17]. BAY 43-9006 is a chemi-
cal inhibitor of B-Raf kinase and reduces phosphorylation
of MEK and ERK [26,27]. VMM18 melanoma cells grown
in the presence of 5% serum had enhanced phosphoryla-
tion of p70S6K and 4EBP1 (Figure 4, lane 2) relative to
cells grown in the absence of serum (Figure 4, PBS, lane
1). The phosphorylation of p70S6K and 4EBP1 retards
migration in SDS-PAGE. Antibodies to these proteins
were used to show all the protein and therefore enable
evaluation of the fraction phosphorylated under different
conditions. Treatment of VMM18 melanoma cells with a
10 nM dose of rapamycin inhibited the serum-stimulated
phosphorylation of p70S6K and 4EBP1 (Figure 4, lane 3).
Parallel treatment of VMM18 melanoma cells with a 10
nM dose of BAY43-9006 unexpectedly inhibited serum-
stimulated phosphorylation of p70S6K and 4EBP1 (Fig-
ure 4, lane 4). There is not a well-documented require-
ment of Raf-MEK-ERK activity for the phosphorylation of
mTOR substrates p70S6K and 4EBP1. Combination treat-
ment with a 10 nM dose of rapamycin plus a 10 nM dose
of BAY43-9006 blocked phosphorylation of p70S6K and
4EBP1 as effectively as either drug alone (Figure 4, lane 5).
Thus, even though cell proliferation was suppressed more
effectively by this combination of drugs, this was not
reflected in a detectable further decrease in phosphoryla-
tion of the mTOR target proteins p70S6K and 4EBP1. As
an additional control, we treated VMM18 melanoma cells
with U0126, a MEK inhibitor, which blocked serum-stim-
ulated phosphorylation of both p70S6K and 4EBP1 (Fig-
ure 4, lane 6). This result showed that MEK/ERK activities
contribute to phosphorylation of p70S6K and 4EBP1.
We noted that total 4EBP1 in cells treated with a combi-
nation of rapamycin plus BAY43-9006, or with U0126,
was lower relative to untreated cells or cells treated with
either rapamycin or BAY43-9006 alone. Equal recovery of
other proteins from the cells was demonstrated by immu-
noblotting both for p70S6K and for GAPDH, used as a
loading control. We do not understand the basis for the
reduced recovery of 4EBP1, but it did not seem to depend
simply on the phosphorylation state because phosphor-
ylation was blocked with the single drug treatments, with-
out change in the level of the 4EBP1 protein.
Rapamycin and BAY43-9006 inhibit phosphorylation of 
proteins in the B-Raf-MEK-ERK signaling pathway in 
melanoma cells
In VMM18 melanoma cells, the dual phosphorylation
(Tyr/Thr) of ERK was 9-fold higher in cells grown in 5%
serum relative to cells grown in the absence of serum (Fig-
ure 5, lanes 2 versus 1). There also was an increased level
in the dual phosphorylation (Ser217/221) of MEK (not
shown). Treatment of VMM18 melanoma cells with a 10
nM dose of BAY 43-9006 produced a 75% decrease in the
dual phosphorylation of ERK (Figure 5, lane 4) and
reduced the phosphorylation of MEK below detection lev-
els (not shown). These results were consistent with the
inhibition of B-Raf by BAY43-9006. On the other hand,
when VMM18 melanoma cells were treated with a 10 nM
dose of rapamycin, the dual phosphorylation of ERK was
reduced by about half (Figure 5, lane 3). Our interpreta-
tion of this result is that mTOR activity is required to
maintain the phosphorylation of ERK in melanoma cells.
Combination treatment of a 10 nM dose of rapamycin
plus a 10 nM dose of BAY 43-9006 reduced the phospho-
rylation of ERK to a level even below that seen in cells
grown in the absence of serum (Figure 5, lane 5). This
inhibition of ERK phosphorylation by combination of
rapamycin and BAY43-9006 was as effective as inhibition
of MEK by the U0126 compound (Figure 5, compare
lanes 5 and 6).
Discussion
New cancer treatments involve directly targeting enzymes
essential for the growth and proliferation of cancer cells.
The mTOR pathway regulates cell growth, and the Raf/
MEK/ERK pathway is critical for cell proliferation. Activat-
ing mutations in B-Raf have been found in 60–70% of
human melanomas, making B-Raf a potential target for
small molecule inhibitors as therapy [3,4,11,28]. Indeed,
new drugs such as BAY43-9006 have been developed as
selective inhibitors of B-Raf and are currently in Phase II
clinical trials [6]. Inhibition of mTOR by rapamycin has
been standard treatment for immunosuppression follow-
ing organ transplant [15], and the rapamycin derivative
CCI-779 is now being clinically tested as a cancer chemo-
therapy [18-20]. Thus, B-Raf and mTOR are acknowl-
edged targets for anti-proliferative therapy [29].Journal of Translational Medicine 2005, 3:39 http://www.translational-medicine.com/content/3/1/39
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Inhibition of various melanoma cell lines by BAY43-9006 and rapamycin Figure 2
Inhibition of various melanoma cell lines by BAY43-9006 and rapamycin. A, The serum-stimulated proliferation of VMM18, 
VMM5A, and VMM39 melanoma cells was assayed in triplicate by Cell Titer Glo (Promega; Madison, WI). Inhibition was deter-
mined as the difference between the number of cells in the control without any added drug compared to the number of cells 
following treatment with an inhibitor. Cells were treated for one hour with doses of BAY43-9006 ranging from 0.01 nM to 100 
nM and were assayed for serum-stimulated proliferation after 48 hours. The mean value for triplicate samples from three inde-
pendent experiments is plotted relative to the control (treated with vehicle, DMSO). Error bars are present at each point on 
the graph. The Student T test was performed and the bracket and asterisk represents a statistically significant difference 
between VMM39 (wt) and VMM5A (V599E) and VMM18 (V599E) cells at the 10 nM concentration with a p value < 0.002. B, 
The serum-stimulated proliferation of VMM18, VMM5A, and VMM39 melanoma cells were assayed as described above except 
melanoma cells were treated with rapamycin instead of BAY43-9006 with doses ranging from 0.01 nM to 100 nM. The mean 
value for triplicate samples from three independent experiments is plotted. Error bars are present at each point on the graph. 
The Student T test was performed and the bracket and asterisk represents a statistically significant difference between VMM39 
(wt) and VMM5A (V599E) and VMM18 (V599E) cells at the 10 nM concentration with a p value < 0.002.
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Isobologram analyses of inhibition of melanoma cell proliferation Figure 3
Isobologram analyses of inhibition of melanoma cell proliferation. A, VMM39 melanoma cells, B, VMM5A melanoma cells, and 
C, VMM18 melanoma cells. The straight line connecting the IC70 points (additivity line) is the locus of all dose pairs that should 
give the same effect. A dose pair (data point) below the line is synergistic, a dose pair on the line is additive, and a dose pair 
above the line is antagonistic. Note: all graphs are on a log-scale.
0.001
0.01
0.1
1
10
0.001 0.01 0.1 1 10
0.001
0.01
0.1
1
10
0.001 0.01 0.1 1 10
B
A
C
0.001
0.01
0.1
1
10
0.001 0.01 0.1 1 10
VMM39
BAY 43-9006 (nM)
R
a
p
a
m
y
c
i
n
 
(
n
M
)
VMM5A
BAY 43-9006 (nM)
R
a
p
a
m
y
c
i
n
 
(
n
M
)
VMM18
BAY 43-9006 (nM)
R
a
p
a
m
y
c
i
n
 
(
n
M
)Journal of Translational Medicine 2005, 3:39 http://www.translational-medicine.com/content/3/1/39
Page 9 of 11
(page number not for citation purposes)
Current knowledge suggests that B-Raf and mTOR protein
kinases operate in separate signaling pathways. The B-Raf
kinase is activated by GTP-Ras in response to growth fac-
tors and phosphorylates MEK, which in turn activates ERK
to phosphorylate downstream targets such as kinases and
transcription factors that promote cell division [30]. The
mTOR kinase responds to both nutrient and growth factor
signals to activate p70S6K and 4EBP1 to increase protein
translation as part of a cell growth response [31]. Increase
in cell growth (size) is a pre-requisite for cell proliferation.
Because the B-Raf and mTOR pathways are thought to
operate in parallel, we hypothesized that combined inhi-
bition of these kinases would be effective in blocking cell
growth and cell proliferation. Though our results with
multiple melanoma cell lines support that hypothesis,
they also gave some unexpected results.
Human tumors deficient in PTEN have activated Akt, and
are especially sensitive to mTOR inhibitors [13]. However,
pharmacogenomic profiling indicates that melanomas are
not, in general, PTEN deficient and therefore would be
unresponsive to mTOR inhibitors. Results from a phase II
trial using CCI-779 alone showed only one response
among 33 observed patients [32]. These data suggest that
CCI-779 is not sufficiently active in melanoma as a single
agent. However, our data show that melanoma cell prolif-
eration is effectively inhibited in vitro by low doses of
rapamycin. Together, these findings argue against use of
CCI-779 as a single agent, but support investigation of
mTOR inhibitors as part of combination therapy for treat-
ment of patients with malignant melanoma.
With regards to B-Raf, recent structural studies have
shown that BAY43-9006 interacts with an inactive confor-
mation of B-Raf [33]. In biochemical assays, the kinase
activity of V599E B-Raf is less sensitive to inhibition by
BAY43-9006 than wild-type B-Raf, suggesting that
melanomas with the B-Raf V599E mutation might be
resistant to the effects of this drug [33]. However, in the
present study, proliferation of the human melanoma cells
was inhibited by BAY43-9006, and at a dose of 10 nM, the
cells that contained mutated B-Raf V599E were more sen-
sitive than cells with wild-type B-Raf. In clinical studies
with BAY43-9006 plus chemotherapy, objective tumor
regressions were more common in patients who had wild-
type B-raf [34]. The findings of the current report support
continued investigation of BAY43-9006 for treatment of
patients with melanoma, and suggest that clinical effects
observed may be due to some effects that are independent
of B-raf kinase activity.
We found that multiple human melanoma cell lines pro-
liferated in culture at different relative rates in the absence
of serum and that the addition of serum to the medium
doubled the rate of proliferation. Thus, we could use the
consistent serum response to compare cell growth and
proliferation with a variety of melanoma cell lines. At con-
centrations in the nanomolar range, we observed dose-
dependent inhibition of cell proliferation by either
rapamycin or BAY43-9006. In every cell line examined,
combination of BAY43-9006 and rapamycin produced
synergistic inhibition of cell proliferation compared to
either drug alone. This suggests that administration of a
combination of an mTOR inhibitor (rapamycin or CCI-
779) and BAY43-9006 could be an especially effective
approach to therapy of melanoma.
Our results indicate that rapamycin and BAY43-9006
inhibit their cognate targets in melanoma cells (mTOR
and B-Raf respectively), as well as downstream effectors
thought to be in other pathways, providing evidence for
cellular cross-talk between the different signaling path-
ways studied. Specifically, we found that BAY43-9006
inhibited serum-stimulated phosphorylation of p70S6K
and 4EBP1, and rapamycin blocked serum-stimulated
phosphorylation of ERK. Previously published results
have suggested interdependence between mTOR and Raf-
MEK-ERK signaling [35-40]. In vascular smooth muscle
cells under hyperglycemic conditions (25 mM versus 5
mM glucose), inhibition of PI3K with LY294002 or inhi-
bition of mTOR by rapamycin reduced the level of ERK
Phosphorylation of mTOR targets in VMM18 melanoma cells  treated with rapamycin, BAY43-9006, or U0126 Figure 4
Phosphorylation of mTOR targets in VMM18 melanoma cells 
treated with rapamycin, BAY43-9006, or U0126. The phos-
phorylation of p70S6K and 4EBP1 was assayed by migration 
in SDS-PAGE and the proteins detected by immunoblotting. 
Control VMM18 cells grown in PBS without serum were ana-
lyzed in lane 1 and VMM18 melanoma cells in lanes 2–6 were 
grown 24 hours in media that contained 5% serum. Cells not 
treated with drugs (lanes 1 and 2) were compared to cells 
pre-treated for one hour with rapamycin (lane 3), BAY43-
9006 (lane 4), a combination of rapamycin and BAY43-9006 
(lane 5), or U0126 (lane 6). GAPDH was immunoblotted as a 
loading control (bottom panel).
4EBP1
p70S6K
GAPDH
P
B
S
N
o
 
d
r
u
g
+
 
B
A
Y
+
 
R
a
p
 
+
 
B
A
Y
+
 
U
0
1
2
6
+
 
R
a
p
+FBS
1 234 6 5
P-4EBP1
P-p70S6KJournal of Translational Medicine 2005, 3:39 http://www.translational-medicine.com/content/3/1/39
Page 10 of 11
(page number not for citation purposes)
Tyr-phosphorylation [35]. In cardiomyocytes, PKC-
dependent activation of mTOR and p70S6K was inhibited
by U0126, implicating a requirement for MEK [36].
Rapamycin inhibited the FGF-2 induced proliferation of
two different small cell lung cancer lines (SCLC), whereas
PD098059 inhibited one and not the other [37]. Combi-
nation of rapamycin and PD098059 was not tested. In
proximal tubular epithelial cells, insulin-activated phos-
phorylation of 4EBP1 could be inhibited by PD098059,
suggesting a requirement for MAPK [38]. Another report
shows that following hypertonic stress, HEK 293 cells
show increase in protein synthesis, and simultaneous
inhibition of both mTOR and ERK was required to pre-
vent de novo translation [39].
Since there appears to be cross-talk between mTOR and
Raf-MEK-ERK pathways, it might be expected that combi-
nation therapy with rapamycin and BAY43-9006 might
simply be additive. To our knowledge, the effects of com-
bining inhibitors of these two pathways on proliferation
of melanoma cells had not previously been examined.
However, studies are in development for such combina-
tion therapies in human clinical trials, sponsored by the
Clinical Trials Evaluation Program (CTEP) of the NIH. In
the present study, we found that the combination of
inhibitors synergistic for inhibition of melanoma cell pro-
liferation.
Cancer cells may be dependent on particular oncogenes
for cell growth, which renders them sensitive to drugs that
inhibit these protein targets. Under these circumstances,
single chemical inhibitors are efficacious, such as Gleevec
inhibition of BCR-ABL in CML [2]. However, in a number
of different cancers, single drug targeted therapy is only
effective in about half of the patients [41]. These cancer
cells utilize either alternate pathways or compensatory
mechanisms to evade inhibition. Under these circum-
stances, combination therapy that inhibits different path-
ways may be especially effective. Our results show
synergistic inhibition of cell proliferation with drugs
against different pathways. Further, we exposed effects on
pathways not thought to be targeted by agents currently
used in the clinic. Because a combination of rapamycin
and BAY43-9006 is more effective at inhibiting
melanoma cell proliferation than either drug alone, fur-
ther studies of this combination in animal models and
clinical trials deserve to be examined.
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